Neoadjuvant PD-1/PD-L1 inhibitors plus chemotherapy in locally advanced gastric cancer: A systematic review and meta-analysis

Key Points

• Combination therapy shows increased effectiveness in improving response rates in gastric cancer patients.
• Key metrics indicate a significant response rate improvement of about 30% in neoadjuvant settings.
• Systematic review and meta-analysis evaluated multiple clinical trials assessing the efficacy of this combined approach.
• Further validation needed across diverse patient demographics to strengthen these findings.